Get the Stockscreener App
104.59
1.67%
1.72
Pre-market:
105.09
0.50
+0.48%
Insmed Inc stock is traded at $104.59, with a volume of 3.69M.
It is up +1.67% in the last 24 hours and up +2.95% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$102.87
Open:
$102.87
24h Volume:
3.69M
Relative Volume:
1.01
Market Cap:
$19.05B
Revenue:
$381.03M
Net Income/Loss:
$-1.01B
P/E Ratio:
-17.58
EPS:
-5.95
Net Cash Flow:
$-789.25M
1W Performance:
+8.42%
1M Performance:
+2.95%
6M Performance:
+43.77%
1Y Performance:
+34.12%
1-Day Range:
$101.74
$105.08
1-Week Range:
$95.27
$105.08
52-Week Range:
$60.40
$106.83
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
104.59 | 18.32B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed (INSM) Price Target Raised to $108 by Morgan Stanley | IN - GuruFocus
What makes Insmed Incorporated stock price move sharplyFree Capital Allocation Plans - beatles.ru
Insmed chief legal officer Smith sells $167,755 in stock By Investing.com - Investing.com Canada
Insmed chair and CEO Lewis sells $699k in shares By Investing.com - Investing.com Canada
Jim Cramer Calls Insmed “Very Speculative” - Yahoo Finance
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' - Benzinga
Insmed(INSM.US) Officer Sells US$5.54 Million in Common Stock - 富途牛牛
JPMorgan Elevates Insmed (INSM) Target Price Amid Positive Outlo - GuruFocus
A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts - Nasdaq
RBC Capital Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
United Therapeutics Faces Key Moment With Tyvaso's Q3 Results - Finimize
Insmed Incorporated(NasdaqGS: INSM) added to Russell 2500 Value Index - MarketScreener
Insmed Surges to 134th in Trading Volume with $612 Million Day Despite Stock Decline - AInvest
Here’s how Insmed grows to be the next $100 billion biotech - STAT
Insmed's Insider Sell-Off: Strategic Exit or Buying Opportunity Ahead of Breakthrough Data? - AInvest
Russell Rebalance: 3 Stocks Ready to Move Higher - MarketBeat
Insider Sell: Roger Adsett Sells 10,686 Shares of Insmed Inc (INSM) - GuruFocus
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110 - Insider Monkey
10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107 - Insider Monkey
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating - Insider Monkey
Is Insmed Stock Overvalued at $98? - Nasdaq
Insmed Completes $750 Million Follow-On Public Offering - Global Legal Chronicle
Is Insmed Stock Overvalued After The 45% Jump? - Forbes
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
Insmed Inc (INSM) Soars 30% on Impressive Study - MSN
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results - Insider Monkey
INSM September 19th Options Begin Trading - Nasdaq
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - Yahoo Finance
Insmed's TPIP: A Breakthrough in Pulmonary Hypertension Therapy with Near-Term Catalysts - AInvest
Insmed (INSM) Soars After Raising $650 million - MSN
Insmed Stock Jumps 29% on Encouraging PAH Study Results - MSN
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com
SEC Form 424B5 filed by Insmed Incorporated - Quantisnow
Insmed prices capital raise of $750 via stock offering - MSN
Insmed announces $650M public offering of common stock - MSN
Insmed Stock Ends Volatile Session Lower, Pauses After Monumental 32% Weekly Surge - Daily Chhattisgarh News
Insmed aims to raise $750M in one of the largest stock offerings this year - Endpoints News
Stocks To Watch: Insmed Sees RS Rating Jump To 93 - MSN
Insmed dips after $750 mln stock sale - TradingView
Insmed (INSM) Secures $750 Million Through Stock Offering - GuruFocus
Insmed is an attractive, but expensive takeout meal - statnews.com
INSM Increases Common Stock Offering to $750M | INSM Stock News - GuruFocus
Insmed Prices $750 Million Common Stock Offering - MarketScreener
Bank of America Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - Defense World
Insmed Announces Pricing of $750 Million Public Offering of Comm - GuruFocus
Insmed Raises Massive $750M in Stock Offering to Advance Breakthrough Drug Pipeline - Stock Titan
INSM: Mizuho Raises Price Target for Insmed to $110 | INSM Stock News - GuruFocus
Insmed Prices Public Offering Of About 7.81 Mln Shares At $96.00/shr - Nasdaq
Insmed raises $750 million in public offering of common stock By Investing.com - Investing.com Canada
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
16.05%
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):